Brokerages expect Biomerica, Inc. (NASDAQ:BMRA) to post earnings per share of ($0.06) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Biomerica’s earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.06). Biomerica reported earnings of ($0.03) per share during the same quarter last year, which suggests a negative year over year growth rate of 100%. The firm is expected to announce its next earnings results on Tuesday, January 15th.
According to Zacks, analysts expect that Biomerica will report full-year earnings of ($0.24) per share for the current year, with EPS estimates ranging from ($0.25) to ($0.22). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.32) per share, with EPS estimates ranging from ($0.37) to ($0.27). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that cover Biomerica.
Biomerica (NASDAQ:BMRA) last announced its quarterly earnings results on Tuesday, October 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. Biomerica had a negative net margin of 31.75% and a negative return on equity of 41.73%. The company had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.38 million.
Biomerica Company Profile
Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.
Further Reading: What is a stock buyback?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.